Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Malignant Lymphoma

  Free Subscription


Articles published in Eur J Haematol

Retrieve available abstracts of 54 articles:
HTML format



Single Articles


    May 2023
  1. CENCINI E, Rocco M, Ghio F, Simonetti F, et al
    Long-term efficacy in patients with relapsed/refractory diffuse large B-cell lymphoma achieving a complete response with pixantrone.
    Eur J Haematol. 2023 May 10. doi: 10.1111/ejh.13989.
    PubMed     Abstract available


    April 2023
  2. METZNER B, Muller TH, Casper J, Kimmich C, et al
    Long-term outcome in patients with mantle cell lymphoma following high-dose therapy and autologous stem cell transplantation.
    Eur J Haematol. 2023 Apr 24. doi: 10.1111/ejh.13985.
    PubMed     Abstract available


    March 2023
  3. ONG SY, Chen Y, Yun MTS, Ho Yew Leng A, et al
    Current perspectives on resistance to CAR T-cell therapy and strategies to improve efficacy in B-cell lymphoma.
    Eur J Haematol. 2023 Mar 29. doi: 10.1111/ejh.13964.
    PubMed     Abstract available


  4. BUEGE MJ, Drill E, Horwitz SM, LeVoir A, et al
    Low incidence of cardiotoxicity in patients with non-Hodgkin lymphoma receiving EPOCH after prior anthracycline exposure.
    Eur J Haematol. 2023 Mar 27. doi: 10.1111/ejh.13971.
    PubMed     Abstract available


  5. KATZ OB, Perry C, Greenzaid SG, Ofir DY, et al
    Response Rates of Extra-Nodal Diffuse Large B Cell Lymphoma to anti CD19-CAR T Cells - a Real Word Retrospective Multi-Center Study.
    Eur J Haematol. 2023 Mar 25. doi: 10.1111/ejh.13968.
    PubMed     Abstract available


  6. MITROVIC Z, Dujmovic D, Jaksic O, Kinda SB, et al
    Dose-adjusted EPOCH and rituximab (DA-EPOCH-R) in older patients with high-risk aggressive diffuse large B-cell lymphoma: a real-life multicenter study by the Croatian Cooperative Group for Hematologic diseases (KroHem).
    Eur J Haematol. 2023 Mar 20. doi: 10.1111/ejh.13957.
    PubMed     Abstract available


  7. SHENG Z, Wang L
    Superiority of ibrutinib plus bendamustine and rituximab in newly diagnosed patients with mantle-cell lymphoma ineligible for intensive therapy: a network meta-analysis.
    Eur J Haematol. 2023 Mar 14. doi: 10.1111/ejh.13953.
    PubMed     Abstract available


    February 2023
  8. GAO H, Lin N, Gu Z, Zhao S, et al
    Up-front Autologous Hematopoietic Stem Cell Transplantation After First Complete Remission Improved Prognosis of Advanced Extra nodal NKT Cell Lymphoma: A Multicenter Real-World Study in China.
    Eur J Haematol. 2023 Feb 24. doi: 10.1111/ejh.13950.
    PubMed     Abstract available


  9. WANG Y, Li J, Xue TL, Tian S, et al
    Clinical, biological and outcome features of P2RY8-CRLF2 and CRLF2 over-expression in pediatric B-cell precursor acute lymphoblastic leukemia according to the CCLG-ALL 2008 and 2018 protocol.
    Eur J Haematol. 2023 Feb 22. doi: 10.1111/ejh.13948.
    PubMed     Abstract available


  10. YUE X, Hallett D, Liu Y, Basa E, et al
    Outcomes of coronavirus disease 2019 (COVID-19) and risk factors associated with severe COVID-19 in patients with mature B-cell non-Hodgkin lymphomas: A US electronic health record cohort study.
    Eur J Haematol. 2023;110:177-187.
    PubMed     Abstract available


  11. SHARGIAN L, Amit O, Bernstine H, Gurion R, et al
    The role of additional chemotherapy prior to autologous HCT in patients with relapse/refractory DLBCL in partial remission-A retrospective multicenter study.
    Eur J Haematol. 2023;110:149-156.
    PubMed     Abstract available


    January 2023
  12. TEY A, Schwarer J, Raffa R, Shi E, et al
    High risk of infection in 'real-world' patients receiving ibrutinib, idelalisib or venetoclax for mature B-cell leukaemia/lymphoma.
    Eur J Haematol. 2023 Jan 19. doi: 10.1111/ejh.13928.
    PubMed     Abstract available


  13. ELLIOTT EK, Hensen R, Haupt LM, Griffiths LR, et al
    Global reported impacts of COVID-19 on lymphoma patients and the emerging clinical management approaches in response to the ongoing pandemic.
    Eur J Haematol. 2023 Jan 19. doi: 10.1111/ejh.13926.
    PubMed     Abstract available


    December 2022
  14. NGUYEN J, Wellard C, Chung E, Cheah CY, et al
    Clinical characteristics of Australian treatment-naive patients with classical Hodgkin Lymphoma from the Lymphoma and Related Diseases Registry.
    Eur J Haematol. 2022 Dec 20. doi: 10.1111/ejh.13915.
    PubMed     Abstract available


  15. PASQUI DM, Latorraca CDOC, Pacheco RL, Riera R, et al
    CAR-T cell therapy for patients with hematological malignancies. A systematic review.
    Eur J Haematol. 2022;109:601-618.
    PubMed     Abstract available


    November 2022
  16. JUUL SJ, Kicinski M, Schaapveld M, Rossetti S, et al
    Comparison of outcomes between Hodgkin's lymphoma patients treated in and outside clinical trials - a study based on the EORTC-Dutch late effects cohort linked data.
    Eur J Haematol. 2022 Nov 11. doi: 10.1111/ejh.13899.
    PubMed     Abstract available


  17. LIU X, Zhao X, Yang J, Wang H, et al
    High expression of AP2M1 correlates with worse prognosis by regulating immune microenvironment and drug resistance to R-CHOP in diffuse large B cell lymphoma.
    Eur J Haematol. 2022 Nov 6. doi: 10.1111/ejh.13895.
    PubMed     Abstract available


    October 2022
  18. RIVA M, Tisi MC, Bertorelle R, Famengo B, et al
    IDH2(R172) mutation in angioimmunoblastic T-cell lymphoma: a retrospective multicenter case series.
    Eur J Haematol. 2022 Oct 20. doi: 10.1111/ejh.13885.
    PubMed    


    September 2022
  19. DE FRANCESCO V, Manta R, Marmo R, Marmo C, et al
    Efficacy of H. pylori eradication in patients with diffuse large B-cell lymphoma of the stomach: a systematic review.
    Eur J Haematol. 2022 Sep 29. doi: 10.1111/ejh.13871.
    PubMed     Abstract available


  20. PAQUIN AR, Oyogoa E, McMurry HS, Kartika T, et al
    The Diagnosis and Management of Suspected Lymphoma in General Practice.
    Eur J Haematol. 2022 Sep 11. doi: 10.1111/ejh.13863.
    PubMed     Abstract available


  21. GILLESSEN S, Pluetschow A, Vucinic V, Ostermann H, et al
    JAK Inhibition with Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma: Final Results of A Phase II, Open Label, Multicenter Clinical Trial (JeRiCHO).
    Eur J Haematol. 2022 Sep 3. doi: 10.1111/ejh.13859.
    PubMed     Abstract available


  22. DANIEL A, Ghez D, Ravaiau C, Cavalieri D, et al
    Ibrutinib as a treatment of hematologic autoimmune disorders in patients with indolent B-cell lymphoma.
    Eur J Haematol. 2022 Sep 1. doi: 10.1111/ejh.13858.
    PubMed     Abstract available


    July 2022
  23. QIU C, Du G
    Loss of LEF-1 expression as a diagnostic indicator for extranodal NK/T-cell lymphoma: An immunohistochemical study of 88 cases.
    Eur J Haematol. 2022 Jul 24. doi: 10.1111/ejh.13836.
    PubMed     Abstract available


  24. CENCINI E, Fabbri A
    Pixantrone in patients with relapsed/refractory diffuse large B-cell lymphoma: A real-life, retrospective, multicenter trial on behalf of the "RTL" (Regional Tuscan Lymphoma network)- authors' reply to Morris and colleagues.
    Eur J Haematol. 2022 Jul 18. doi: 10.1111/ejh.13831.
    PubMed    


  25. MORRIS J, O'Reilly M, Sargent J, Murphy P, et al
    Pixantrone as a bridge to CAR-T treatment in high-grade transformation of follicular lymphoma.
    Eur J Haematol. 2022 Jul 18. doi: 10.1111/ejh.13829.
    PubMed    


    June 2022
  26. ABBASOV E, Metzner B, Muller TH, Casper J, et al
    Herpes Zoster prophylaxis with low-dose acyclovir in patients with malignant lymphoma and multiple myeloma treated with autologous stem cell transplantation (ASCT).
    Eur J Haematol. 2022 Jun 10. doi: 10.1111/ejh.13810.
    PubMed     Abstract available


    May 2022
  27. VODICKA P, Benesova K, Janikova A, Prochazka V, et al
    Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world.
    Eur J Haematol. 2022 May 3. doi: 10.1111/ejh.13784.
    PubMed     Abstract available


    April 2022

  28. Retracted: Bevacizumab synergises with the BCL 2 inhibitor venetoclax to effectively treat B-cell non-Hodgkin's lymphoma.
    Eur J Haematol. 2022 Apr 27. doi: 10.1111/ejh.13776.
    PubMed    


    March 2022
  29. PENICHOUX J, Rio J, Kammoun L, Vermeulin T, et al
    Retrospective analysis of the safety of peripherally inserted catheters versus implanted port catheters during first-line treatment for patients with diffuse large B-cell lymphoma.
    Eur J Haematol. 2022 Mar 13. doi: 10.1111/ejh.13767.
    PubMed     Abstract available


  30. EZE C, Friedrich I, Hadi I, Schmidt-Hegemann NS, et al
    Primary radiation therapy in stage I/II indolent orbital lymphoma - a comprehensive retrospective recurrence and toxicity analysis.
    Eur J Haematol. 2022 Mar 11. doi: 10.1111/ejh.13765.
    PubMed     Abstract available


    January 2022
  31. GRAEF CM, Godel P, Falderbaum P, Balke-Want H, et al
    Impact of timing and precision of histopathological diagnosis on outcomes of patients with Burkitt Lymphoma and High-Grade B-Cell Lymphoma.
    Eur J Haematol. 2022 Jan 28. doi: 10.1111/ejh.13747.
    PubMed     Abstract available


  32. CENCINI E, Mecacci B, Rocco M, Innocenti F, et al
    Pixantrone in patients with relapsed/refractory diffuse large b-cell lymphoma: A real-life, retrospective, multicenter trial on behalf of the "RTL" (Regional Tuscan Lymphoma Network).
    Eur J Haematol. 2022 Jan 20. doi: 10.1111/ejh.13745.
    PubMed     Abstract available


  33. FU H, Shen J, Zhou H, Zhang F, et al
    Mutation profiling of circulating tumor DNA identifies distinct mutation patterns in non-Hodgkin lymphoma.
    Eur J Haematol. 2022 Jan 7. doi: 10.1111/ejh.13736.
    PubMed     Abstract available


  34. BEYAR-KATZ O, Kikozashvili N, Bar On Y, Amit O, et al
    Characteristics and recognition of early infections in patients treated with commercial anti-CD19 CAR-T cells.
    Eur J Haematol. 2022;108:52-60.
    PubMed     Abstract available


    December 2021
  35. NOSAKA K, Crawford B, Yi J, Kuan W, et al
    A Systematic Review of Survival Outcomes for Relapsed or Refractory Adult T-Cell Leukemia-Lymphoma.
    Eur J Haematol. 2021 Dec 4. doi: 10.1111/ejh.13728.
    PubMed     Abstract available


  36. WEISSINGER SE, Zahn M, Marienfeld R, Tessmer C, et al
    Combination of two monoclonal antibodies with SOCS1 N- and C-terminal binding sites to address SOCS1 status in B cells and B-cell lymphoma.
    Eur J Haematol. 2021 Dec 1. doi: 10.1111/ejh.13730.
    PubMed     Abstract available


    November 2021
  37. CUNNINGHAM I, Sosa SS, Hamele-Bena D
    A single organ microenvironment and the common features of tumors of leukemia, lymphoma, and myeloma cells growing there. A literature review.
    Eur J Haematol. 2021 Nov 15. doi: 10.1111/ejh.13727.
    PubMed     Abstract available


  38. SMITH T, Cunningham-Rundles C
    Lymphoid malignancy in common variable immunodeficiency in a single-center cohort.
    Eur J Haematol. 2021;107:503-516.
    PubMed     Abstract available


    October 2021
  39. FREITAS AC, Carvalho IP, Esteves S, Salgado L, et al
    End of treatment FDG-PET in primary mediastinal B-cell lymphoma treated with R-chemotherapy: Prognostic indicator and implications for consolidation radiotherapy.
    Eur J Haematol. 2021 Oct 2. doi: 10.1111/ejh.13715.
    PubMed     Abstract available


  40. LACOMBE V, Nunes Gomes C, Robin JB, Thepot S, et al
    Risk of infection according to the gamma globulin level in the 100 days following allogeneic stem cell transplantations.
    Eur J Haematol. 2021;107:489-496.
    PubMed     Abstract available


    September 2021
  41. BRIAND M, Gerard S, Gauthier M, Garric M, et al
    Impact of therapeutic management and geriatric evaluation on patient of 80 years and older with diffuse large B-cell lymphoma on survival: a systematic review.
    Eur J Haematol. 2021 Sep 8. doi: 10.1111/ejh.13704.
    PubMed     Abstract available


  42. KUIJVENHOVEN MA, Wilhelm AJ, Meijer E, Janssen JJWM, et al
    TRough versus AUC Monitoring of cyclosporine: A randomized comparison of adverse drug reactions in adult allogeneic stem cell recipients (TRAM study).
    Eur J Haematol. 2021;107:364-369.
    PubMed     Abstract available


  43. VERLINDEN A, Schroyens WA, Gadisseur AP
    Clinical and microbiological impact of long-term discontinuation of fluoroquinolone prophylaxis in haematological patients with prolonged profound neutropenia.
    Eur J Haematol. 2021;107:377-379.
    PubMed    


  44. ATTMAN E, Syrjanen J, Lyytikainen O, Ollgren J, et al
    Healthcare-associated blood stream infections in hematological patients in Finland during the years 2006-2016.
    Eur J Haematol. 2021;107:311-317.
    PubMed     Abstract available


    July 2021
  45. METZNER B, Pott C, Muller TH, Casper J, et al
    Long-term outcome in patients with follicular lymphoma following high-dose therapy and autologous stem cell transplantation.
    Eur J Haematol. 2021 Jul 20. doi: 10.1111/ejh.13691.
    PubMed     Abstract available


  46. WIGHT J, Wai SH, Shen E, Lee ST, et al
    Predicting primary treatment failure using interim FDG-PET scanning in Diffuse large B-cell lymphoma.
    Eur J Haematol. 2021 Jul 8. doi: 10.1111/ejh.13684.
    PubMed     Abstract available


  47. WU X, Nowakowski KE, Abeykoon JP, Manske M, et al
    MCIR1: A Patient-Derived Mantle Cell Lymphoma Line for Discovering New Treatments for Ibrutinib Resistance.
    Eur J Haematol. 2021 Jul 2. doi: 10.1111/ejh.13682.
    PubMed     Abstract available


  48. MORTENSEN JB, Monrad I, Enemark MB, Ludvigsen M, et al
    Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.
    Eur J Haematol. 2021;107:81-91.
    PubMed     Abstract available


  49. WEISSINGER SE, Zahn M, Marienfeld R, Tessmer C, et al
    A new reliable and highly specific monoclonal antibody to detect the C-terminal region of silencer of cytokine signaling 1.
    Eur J Haematol. 2021;107:74-80.
    PubMed     Abstract available


    May 2021
  50. RENAUD L, Bossard JB, Carpentier B, Terriou L, et al
    Treatment with temozolomide and ibrutinib in Recurrent/Refractory Primary (PCNSL) and Secondary CNS Lymphoma (SCNSL).
    Eur J Haematol. 2021 May 21. doi: 10.1111/ejh.13667.
    PubMed     Abstract available


  51. SHANMUGASUNDARAM K, Goyal S, Switchenko J, Calzada O, et al
    Intensive Induction Regimens after Deferring Initial Therapy for Mantle Cell Lymphoma Are Not Associated with Improved Survival.
    Eur J Haematol. 2021 May 11. doi: 10.1111/ejh.13649.
    PubMed     Abstract available


  52. SIEG N, Naendrup JH, Godel P, Balke-Want H, et al
    Treatment patterns and disease course of previously untreated Primary Central Nervous System Lymphoma - feasibility of MTX-based regimens in clinical routine.
    Eur J Haematol. 2021 May 7. doi: 10.1111/ejh.13639.
    PubMed     Abstract available


  53. HANSEN S, Alduaij W, Biggs CM, Belga S, et al
    Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series.
    Eur J Haematol. 2021;106:654-661.
    PubMed     Abstract available


    April 2021
  54. YUDA S, Maeshima AM, Taniguchi H, Ito Y, et al
    Clinicopathological factors and tumor microenvironment markers predicting watch-and-wait discontinuation in 82 patients with follicular lymphoma.
    Eur J Haematol. 2021 Apr 27. doi: 10.1111/ejh.13637.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: